Prostate News and Research

RSS

A review of PSA use in screening for prostate cancer

Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.

19 Jun 2007

Solvay Pharmaceuticals submits supplemental NDA for AndroGel

Solvay Pharmaceuticals, Inc., has announced that it submitted a supplemental New Drug Application (sNDA) for AndroGel (testosterone gel) 1% CIII to the U.S. Food and Drug Administration (FDA) for treatment in male adolescents ages 13-17 years old with primary or secondary hypogonadism.

17 Jun 2007

Diagnosing cancer at early stages imperative for survival

Early detection of cancer through regular screenings can greatly increase survival rates because it identifies cancer when it's most treatable, according to the National Cancer Institute.

17 Jun 2007

Folic acid supplements do not reduce risk of precancerous colon tumors

Taking folic acid supplements does not reduce the risk of developing precancerous tumors in the colon and may even increase the risk, a new study has found.

16 Jun 2007

Trial shows nanoparticle-enabled thermal therapy safe for treating cancer

Several types of metal nanoparticles are capable of converting energy, such as that carried by near-infrared light or an oscillating magnetic field, into heat at a level high enough to kill tumors.

14 Jun 2007

BRCA2 carriers more likely to develop aggressive and lethal prostate cancer

Carriers of a BRCA2 variation specific to Iceland are more likely to develop aggressive and lethal prostate cancer than noncarriers, according to a study published online in the Journal of the National Cancer Institute.

14 Jun 2007

New contributor to aggressive cancers

Mutations in the cell adhesion molecule known as integrin alpha 7 (integrin 7) lead to unchecked tumor cell proliferation and a significantly higher incidence in cancer spread, or metastasis, in several cancer cell lines, report researchers at the University of Pittsburgh School of Medicine in a study published in the Journal of the National Cancer Institute.

8 Jun 2007

African-American men understimate risk of prostate cancer

Many African-American men radically underestimate the likelihood that having a needle biopsy for suspected prostate cancer will result in a cancer diagnosis, according to a study from the University of Chicago Medical Center.

5 Jun 2007

Circulating tumor cells predict how prostate cancer patients do with chemotherapy

The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial.

5 Jun 2007

Treatment for early prostate cancer associated with type of specialist seen

A new study analyzing men with localized prostate cancer shows that the specialty of the physician they see can influence the type of therapy they ultimately receive.

5 Jun 2007

Bone-targeting radioisotope radium-223 for prostate cancer treatment

The bone-targeting radioisotope radium-223 has delivered promising results in a randomised trial to test its efficacy in treatment of hormone-refractory prostate cancer (HRPC).

5 Jun 2007

Findings from study of immunotherapy vaccine in prostate cancer patients

Data from an ongoing study designed to explore the biologic and clinical activity of cancer immunotherapy sipuleucel-T, or Provenge, in patients with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic disease will be presented by Oregon Health & Science University Cancer Institute researchers.

5 Jun 2007

Gabapentin reduces hot flashes in men receiving androgen deprivation therapy

North Central Cancer Treatment Group ( http://ncctg/ ) researchers based at Mayo Clinic ( http://www.mayo.edu/ ) in Rochester, Minn., have discovered that low doses of a drug used to prevent epileptic seizures and to treat nerve pain caused by shingles substantially reduces hot flashes in patients who are undergoing anti-hormonal treatment, or androgen-deprivation therapy, for prostate cancer.

5 Jun 2007

Gene therapy delivery of nerve growth factors reverses erectile dysfunction in mice

Rats with erectile dysfunction, or ED, that were injected with a gene therapy vector containing either of two nerve growth factors were able to regain normal function after four weeks, according to a study conducted by University of Pittsburgh School of Medicine researchers.

5 Jun 2007